Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial.
about
Human papilloma virus and squamous cell carcinoma of the anusKRAS, BRAF and PIK3CA status in squamous cell anal carcinoma (SCAC)Efficacy and toxicity of chemoradiation in patients with anal cancer--a retrospective analysis.Anal squamous cell carcinoma: an evolution in disease and management.Anal cancer treatment: current status and future perspectives.HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205).Comprehensive multiplatform biomarker analysis of 199 anal squamous cell carcinomas.A phase II open-label multicenter study of gefitinib in combination with irradiation followed by chemotherapy in patients with inoperable stage III non-small cell lung cancerShifting paradigm in the management of anal canal carcinoma.Pharmacotherapy of Anal Cancer.Advances in the Management of Anal Cancer.Significance of Co-expression of Epidermal Growth Factor Receptor and Ki67 on Clinical Outcome in Patients With Anal Cancer Treated With Chemoradiotherapy: An Analysis of NRG Oncology RTOG 9811.No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC).Targeting phosphorylation of STAT3 delays tumor growth in HPV-negative anal squamous cell carcinoma mouse model.Trial Watch: Radioimmunotherapy for oncological indications.Background and Current Treatment of Squamous Cell Carcinoma of the Anus.Toxicity of concomitant cetuximab and radiotherapy with or without initial taxane-based induction chemotherapy in locally advanced head and neck cancer.
P2860
Q26820863-0D86381C-CC04-4B8F-B1F3-5E72E4F94197Q28541078-918A194C-3B3C-485D-BD8B-1FF7B7B908F9Q33646367-3E99074D-3C4E-4FF5-8F19-59C84C91423AQ34255528-0FE2DD11-577D-462B-AC27-70866D918C93Q34465769-AC8092A1-7A80-47BF-8A7C-842D9DCB31B0Q35475401-8A5B4105-FD9D-4CBA-B668-E56797A02DC8Q36244369-1E10D201-7E12-419B-8CFA-49EC036C4EA2Q36685452-086E2A0A-AFBF-48D8-90C6-4C63E0EAD17AQ37716645-E33577B6-EFD2-469F-92FB-A84ADC258DD9Q38272464-171BB901-BA76-464F-8800-D8DEE700B8DFQ38647761-52B6A1E9-32C8-4C5D-A924-A0C4C7099661Q38746232-60C7BC06-9898-42F2-B946-75BE49188126Q38996898-78DFE3FA-29F6-48AE-8422-02E77FF19B7CQ39154481-F77E1B30-6DB5-4251-9619-8BE69A943244Q41140931-302E46A0-BF5E-4B91-81F5-EA3D7653AD00Q43104064-0107025E-390D-426A-A3DA-13C69836420AQ50897271-419B8BB2-B252-4D1D-8624-00B708666430Q53507332-D95B6E85-070E-4B1B-BF0C-A157157A14B0
P2860
Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Unexpected toxicity of cetuxim ...... NCER ACCORD 16 phase II trial.
@en
Unexpected toxicity of cetuxim ...... NCER ACCORD 16 phase II trial.
@nl
type
label
Unexpected toxicity of cetuxim ...... NCER ACCORD 16 phase II trial.
@en
Unexpected toxicity of cetuxim ...... NCER ACCORD 16 phase II trial.
@nl
prefLabel
Unexpected toxicity of cetuxim ...... NCER ACCORD 16 phase II trial.
@en
Unexpected toxicity of cetuxim ...... NCER ACCORD 16 phase II trial.
@nl
P2093
P921
P356
P1433
P1476
Unexpected toxicity of cetuxim ...... ANCER ACCORD 16 phase II trial
@en
P2093
A Delarochefordiere
C Lemanski
I Martel-Lafay
K Malekzadeh
P304
P356
10.1093/ANNONC/MDT368
P577
2013-09-11T00:00:00Z